BAX [NYSE]
Baxter International Inc.
IndexS&P 500 P/E31.28 EPS (ttm)2.09 Insider Own0.20% Shs Outstand503.00M Perf Week1.92%
Market Cap32.02B Forward P/E14.01 EPS next Y4.66 Insider Trans-6.60% Shs Float502.50M Perf Month-13.86%
Income1.06B PEG2.23 EPS next Q0.88 Inst Own88.90% Short Float1.17% Perf Quarter-17.32%
Sales13.54B P/S2.36 EPS this Y18.60% Inst Trans2.23% Short Ratio1.78 Perf Half Y-24.65%
Book/sh18.04 P/B3.62 EPS next Y12.52% ROA4.00% Target Price86.85 Perf Year-20.09%
Cash/sh4.67 P/C13.96 EPS next 5Y14.05% ROE11.90% 52W Range63.25 - 89.70 Perf YTD-23.99%
Dividend1.16 P/FCF40.22 EPS past 5Y-22.50% ROI5.50% 52W High-27.26% Beta0.68
Dividend %1.78% Quick Ratio1.40 Sales past 5Y4.70% Gross Margin39.40% 52W Low3.16% ATR2.02
Employees60000 Current Ratio2.10 Sales Q/Q25.80% Oper. Margin10.50% RSI (14)33.93 Volatility3.06% 2.85%
OptionableYes Debt/Eq1.89 EPS Q/Q-76.10% Profit Margin7.80% Rel Volume0.77 Prev Close66.71
ShortableYes LT Debt/Eq1.85 EarningsMay 25 BMO Payout53.10% Avg Volume3.31M Price65.25
Recom2.00 SMA20-6.78% SMA50-9.46% SMA200-17.78% Volume2,548,930 Change-2.19%
Jun-24-22Downgrade Wells Fargo Overweight → Equal Weight $71
Apr-04-22Downgrade Goldman Neutral → Sell $88 → $77
Mar-02-22Resumed BofA Securities Buy $100
Feb-18-22Reiterated Wells Fargo Overweight $95 → $93
Feb-18-22Reiterated UBS Neutral $88 → $91
Feb-18-22Reiterated Stifel Buy $90 → $91
Feb-18-22Reiterated Raymond James Outperform $99 → $96
Feb-18-22Reiterated Morgan Stanley Overweight $110 → $105
Feb-18-22Reiterated KeyBanc Capital Markets Overweight $98 → $95
Feb-11-22Initiated Goldman Neutral $91
Jan-07-22Upgrade Morgan Stanley Equal-Weight → Overweight $86 → $110
Jan-07-22Resumed Citigroup Buy $101
Sep-13-21Upgrade Cowen Market Perform → Outperform $98
Sep-03-21Upgrade Barclays Equal Weight → Overweight $93 → $100
May-25-21Initiated Barclays Equal Weight $93
Jan-29-21Downgrade Piper Sandler Overweight → Neutral $100 → $80
Jan-06-21Downgrade UBS Buy → Neutral $95 → $85
Dec-15-20Downgrade Goldman Buy → Neutral $96 → $85
Oct-01-20Upgrade Citigroup Neutral → Buy $94
Sep-04-20Downgrade Argus Buy → Hold
Jun-27-22 04:51PM  
08:00AM  
Jun-23-22 09:42AM  
Jun-11-22 10:39AM  
Jun-08-22 04:15PM  
Jun-06-22 10:52AM  
Jun-03-22 11:32AM  
Jun-02-22 04:15PM  
11:31AM  
May-25-22 09:00AM  
May-24-22 01:49PM  
May-10-22 04:15PM  
May-06-22 07:33AM  
May-03-22 07:45AM  
Apr-28-22 10:54AM  
08:35AM  
07:15AM  
Apr-27-22 11:00AM  
07:13AM  
Apr-21-22 03:01PM  
10:35AM  
09:16AM  
Apr-19-22 05:27PM  
05:27PM  
09:00AM  
Apr-14-22 03:27PM  
07:40AM  
Apr-06-22 11:24AM  
Apr-05-22 02:55PM  
09:00AM  
Apr-04-22 11:51AM  
Apr-02-22 06:43PM  
Mar-23-22 05:26PM  
Mar-18-22 11:00AM  
Mar-16-22 11:39AM  
Mar-15-22 11:54AM  
08:00AM  
Mar-14-22 11:09AM  
Mar-10-22 12:48PM  
12:17PM  
Mar-01-22 04:15PM  
09:00AM  
Feb-23-22 09:08AM  
Feb-22-22 04:53PM  
04:30PM  
04:15PM  
10:50AM  
Feb-21-22 10:34AM  
09:56AM  
Feb-19-22 05:21PM  
Feb-18-22 12:02PM  
11:38AM  
10:23AM  
Feb-17-22 11:03AM  
10:05AM  
08:35AM  
07:15AM  
Feb-15-22 11:40AM  
Feb-14-22 05:15PM  
11:35AM  
Feb-11-22 05:50PM  
10:56AM  
10:39AM  
Feb-10-22 04:15PM  
03:01PM  
10:11AM  
07:00AM  
Feb-08-22 09:38AM  
Feb-07-22 08:38PM  
12:10PM  
09:49AM  
09:40AM  
04:12AM  
Feb-03-22 01:33PM  
01:09PM  
12:38PM  
12:30PM  
12:14PM  
Feb-02-22 11:43PM  
09:38PM  
11:38AM  
09:06AM  
05:49AM  
Feb-01-22 05:38PM  
01:38PM  
11:55AM  
Jan-31-22 11:43AM  
08:58AM  
Jan-28-22 11:04AM  
Jan-27-22 05:38PM  
05:38PM  
11:42AM  
08:32AM  
Jan-26-22 09:38AM  
Jan-25-22 01:17PM  
10:56AM  
Jan-24-22 09:52AM  
Jan-21-22 09:38AM  
Jan-20-22 08:23AM  
Jan-19-22 11:50AM  
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HELLMAN PETER SDirectorApr 05Option Exercise29.524,020118,67031,649Apr 07 04:05 PM
STROUCKEN ALBERT P LDirectorApr 05Option Exercise29.524,020118,67038,147Apr 07 04:07 PM
STROUCKEN ALBERT P LDirectorApr 05Sale76.024,020305,61234,127Apr 07 04:07 PM
HELLMAN PETER SDirectorApr 05Sale76.024,020305,59327,629Apr 07 04:05 PM
FORSYTH JOHN DDirectorApr 01Option Exercise29.521,00529,66828,034Apr 05 04:57 PM
FORSYTH JOHN DDirectorApr 01Sale77.681,00578,06827,029Apr 05 04:57 PM
FORSYTH JOHN DDirectorMar 01Option Exercise29.521,00529,66828,034Mar 03 04:07 PM
FORSYTH JOHN DDirectorMar 01Sale84.821,00585,24427,029Mar 03 04:07 PM
Stevens BrianSVP, CAO and ControllerFeb 28Sale85.502,500213,75714,011Mar 01 04:13 PM
Mason Jeanne KSVP, Human ResourcesFeb 14Option Exercise30.9554,1431,675,726175,242Feb 16 04:05 PM
Mason Jeanne KSVP, Human ResourcesFeb 14Sale85.0254,1434,603,078121,099Feb 16 04:05 PM
Chen Thomas FDirectorFeb 02Option Exercise35.031,68058,85014,667Feb 03 04:05 PM
Chen Thomas FDirectorFeb 02Sale84.531,680142,01012,987Feb 03 04:05 PM
FORSYTH JOHN DDirectorFeb 01Option Exercise29.521,00529,66828,034Feb 03 04:04 PM
FORSYTH JOHN DDirectorFeb 01Sale85.591,00586,01827,029Feb 03 04:04 PM
Kunzler JacquelineSVP, Chief Quality OfficerJan 07Option Exercise30.952,21568,5548,341Jan 11 04:30 PM
Martin SeanSVP and General CounselNov 01Option Exercise50.7721,4501,089,01663,731Nov 03 04:06 PM
Martin SeanSVP and General CounselNov 01Sale79.5721,4501,706,70642,281Nov 03 04:06 PM
Martin SeanSVP and General CounselAug 02Option Exercise50.7719,8001,005,24661,977Aug 04 04:09 PM
Martin SeanSVP and General CounselAug 02Sale77.2619,8001,529,74842,177Aug 04 04:09 PM